This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the IBRANCE® Summary of Product Characteristics for Great Britain. IBRANCE® (palbociclib) Prescribing Information for Great Britain click here. IBRANCE® (palbociclib) Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Dosing 

Confidence Through Simplicity1

IBRANCE® has a convenient, once daily, oral regimen.

​​​​​​​The recommended starting dose is 125 mg of IBRANCE® once daily for 21 consecutive days followed by 7 days off treatment (schedule 3/1) to comprise a complete cycle of 28 days.1

Treatment with IBRANCE® should be continued as long as the patient is deriving clinical benefit from therapy or until unacceptable toxicity occurs.1

IBRANCE® 4 Week Dosing Schedule


​​​​​​​How to take IBRANCE®

IBRANCE® can be taken with or without food. No additional dose should be taken if a dose is missed, and the next prescribed dose should be taken at the usual time. IBRANCE® should be swallowed whole, not chewed, crushed or opened prior to swallowing.1

Available Doses 

IBRANCE® is available in 3 dose levels to facilitate dose modification.1

IBRANCE® Dose Levels


​​​​​​​It is important for patients to start on the 125 mg daily dose as the majority of patients treated with IBRANCE® do not require a dose reduction.2,3

In the PALOMA Clinical Trial Programme ≥1 dose reduction due to adverse events were recorded in 36% of IBRANCE®-treated patients in PALOMA-2 and in 34% in PALOMA-3.2,3

​​​​​​​If further dose reduction below 75 mg/day is required, discontinue IBRANCE®.​​​​​​​1

As with all medications, IBRANCE® may interact with certain drugs. Please refer to the IBRANCE® Summary of Product Characteristics for a complete list of drug-drug interactions.


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

References
  1. IBRANCE® Summary of Product Characteristics for Great Britain click here. IBRANCE® Summary of Product Characteristics for Northern Ireland click here.
  2. Cristofanilli M, et al. Lancet Oncol. 2016;17(4):425-439.
  3. Finn RS, et al. N Engl J Med. 2016;375:1925-36. Supplementary appendix.
PP-IBR-GBR-3727. July 2021

Dosing

Dosing and Monitoring requirements for IBRANCE®

  • Monitoring Requirements

Clinical Trials

  • Clinical Trial results for IBRANCE®
  • IBRANCE® Clinical Trials
  • PALOMA-2 Trial

Safety

IBRANCE® safety information and outcomes
  • IBRANCE® Safety Profile
  • Neutropenia
  • Adverse Event Management

Indication

  • IBRANCE® is indicated for the treatment of HR+/HER2- locally advanced or metastatic breast cancer:
       - In combination with an aromatase inhibitor; or
    ​​​​​​​   - In combination with fulvestrant in women who have received prior ET

    In pre- or perimenopausal women, the ET should be combined with a LHRH agonist

Ask Pfizer

Connect virtually with a Pfizer representative to discuss promotional information on a selected range of products.

Book now

Ask Pfizer

Connect virtually with a Pfizer representative to discuss promotional information on a selected range of products.

Book now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No